Phase III SELECT-GCA study of upadacitinib (Rinvoq) showed positive results in patients with giant cell arteritis.- AbbVie.
AbbVie announced positive top-line results from SELECT-GCA, a Phase III, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (Rinvoq; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remission from week 12 through week 52 in adults with giant cell arteritis (GCA).